REGENXBIO Inc. (RGNX)
Biological Products, (No Diagnostic Substances) · market cap $506M
Research and calibrated estimates, not financial advice — verify before acting.
- 2026-12-15 (est.)Phase 3 · Ranibizumab (LUCENTIS®)imp 9/10
- 2026-12-31Data Readoutimp 5/10
- 2027-01-01 (est.)Phase 3imp 8/10
- 2027-02-17 (est.)PDUFA · RGX-121imp 8/10
- 2027-05-09 (est.)PDUFA · Regenxbio gene therapy (unnamed)imp 8/10
- 2027-07-01BLA Filingimp 7/10
| Asset | Phase | Indication |
|---|---|---|
| Aflibercept (EYLEA®) | Phase 3 | AMD |
| Local Steroid | Phase 2 | Neovascular Age-Related Macular Degeneration (nAMD) |
| Topical Steroid | Phase 2 | Neovascular Age-Related Macular Degeneration (nAMD) |
Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
- SEC filings — EDGAR filings for RGNX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.
